Published in J Clin Invest on January 01, 1991
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med (2016) 4.33
Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci U S A (1996) 3.17
Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J Virol (1995) 2.87
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst (1996) 2.11
TAP-independent, beta 2-microglobulin-dependent surface expression of functional mouse CD1.1. J Exp Med (1995) 1.96
Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 1.86
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69
Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest (1996) 1.64
Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J Virol (1997) 1.63
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res (1995) 1.45
Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A (2006) 1.39
Cancer vaccines: progress reveals new complexities. J Clin Invest (2002) 1.29
Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A (1994) 1.29
Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports (2014) 1.25
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest (1991) 1.21
Photoaffinity antigens for human gammadelta T cells. J Immunol (2008) 1.19
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. J Immunother Emphasis Tumor Immunol (1994) 1.16
Rapid degradation of the heavy chain of class I major histocompatibility complex antigens in the endoplasmic reticulum of human cytomegalovirus-infected cells. J Virol (1994) 1.12
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol (1993) 1.06
Calnexin retains unassembled major histocompatibility complex class I free heavy chains in the endoplasmic reticulum. J Exp Med (1994) 1.03
Does the immune system naturally protect against cancer? Front Immunol (2014) 1.02
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. J Immunother Emphasis Tumor Immunol (1995) 0.99
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell (2017) 0.94
Therapeutic potential and challenges of natural killer cells in treatment of solid tumors. Front Immunol (2015) 0.93
An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med (1994) 0.90
The heavy chain of neonatal Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of beta2-microglobulin association. Biochem J (2002) 0.89
Assumptions of the tumor 'escape' hypothesis. Semin Cancer Biol (2002) 0.89
Activity-dependent regulation of MHC class I expression in the developing primary visual cortex of the common marmoset monkey. Behav Brain Funct (2011) 0.86
Stromal cells from human decidua exert a strong inhibitory effect on NK cell function and dendritic cell differentiation. PLoS One (2014) 0.83
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line. J Immunother Emphasis Tumor Immunol (1995) 0.82
NAC, tiron and trolox impair survival of cell cultures containing glioblastoma tumorigenic initiating cells by inhibition of cell cycle progression. PLoS One (2014) 0.81
Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules. Br J Cancer (1999) 0.80
Enhancing the recognition of tumour associated antigens. Folia Biol (Praha) (1994) 0.80
Lack of MHC class I surface expression on neoplastic cells and poor activation of the secretory pathway of cytotoxic cells in oral squamous cell carcinomas. Br J Cancer (1999) 0.80
Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT? Bone Marrow Transplant (2015) 0.79
Loss of human leucocyte antigen class I and gain of class II expression are early events in carcinogenesis: clues from a study of Barrett's oesophagus. J Clin Pathol (2006) 0.79
Identification and characterization of an alternatively spliced variant of the MHC class I-related porcine neonatal Fc receptor for IgG. Dev Comp Immunol (2008) 0.79
The failure of Daudi cells to express the cellular prion protein is caused by a lack of glycosyl-phosphatidylinositol anchor formation. Immunology (2001) 0.77
Distribution of candidate genes for experimentally induced arthritis in rats. BMC Genomics (2010) 0.77
Decoding the Structural Bases of D76N ß2-Microglobulin High Amyloidogenicity through Crystallography and Asn-Scan Mutagenesis. PLoS One (2015) 0.77
Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. Cancer Gene Ther (2012) 0.77
False homozygosity results in HLA genotyping due to loss of chromosome 6 in a patient with acute lymphoblastic leukemia. Korean J Lab Med (2011) 0.75
Immunotherapy resistance: the answers lie ahead - not in front - of us. J Immunother Cancer (2017) 0.75
Generation of murine tumor cell lines deficient in MHC molecule surface expression using the CRISPR/Cas9 system. PLoS One (2017) 0.75
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. Oncotarget (2016) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem (1983) 206.01
A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem (1974) 113.22
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A (1980) 109.70
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun (1978) 32.33
Enhancer-dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A (1984) 17.51
Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell (1978) 14.82
In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today (1990) 10.84
Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin. Proc Natl Acad Sci U S A (1981) 7.24
Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. Proc Natl Acad Sci U S A (1981) 6.03
Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell (1981) 5.81
Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc Natl Acad Sci U S A (1980) 4.35
Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods (1984) 4.15
Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature (1982) 3.74
Characterization of a monoclonal anti-beta 2-microglobulin antibody and its use in the genetic and biochemical analysis of major histocompatibility antigens. Eur J Immunol (1979) 3.27
Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J Immunol (1989) 3.24
The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol (1987) 3.09
NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol (1987) 3.06
Structure of wild-type and mutant mouse beta 2-microglobulin genes. Cell (1982) 2.97
The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta2 microglobulin. Tissue Antigens (1978) 2.40
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A (1989) 2.32
The beta2-microglobulin gene is on chromosome 15 and not in the HL-A region. Nature (1975) 2.29
The beta2-microglobulin mRNA in human Daudi cells has a mutated initiation codon but is still inducible by interferon. EMBO J (1983) 2.28
Beta 2-microglobulin is not required for cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db. Proc Natl Acad Sci U S A (1986) 2.26
Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med (1985) 2.12
De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. Proc Natl Acad Sci U S A (1989) 1.90
c-myc down-regulates class I HLA expression in human melanomas. EMBO J (1988) 1.72
Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol (1988) 1.60
Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci U S A (1986) 1.56
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
HLA restriction of human cytotoxic T cells. Springer Semin Immunopathol (1980) 1.38
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Increased resistance to non-MHC-restricted cytotoxicity related to HLA A, B expression. Direct demonstration using beta 2-microglobulin-transfected Daudi cells. J Immunol (1988) 1.31
Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene. J Exp Med (1988) 1.24
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma. J Exp Med (1989) 1.23
Expression of H-2Db on the cell surface in the absence of detectable beta 2 microglobulin. J Exp Med (1984) 1.23
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol (1981) 1.21
Functional role of HLA class I cell-surface molecules in human T-lymphocyte activation and proliferation. Proc Natl Acad Sci U S A (1986) 1.19
The component fragments obtained by acid dissociation of papain-solubilized H-2 molecules. J Immunogenet (1976) 1.18
Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol (1987) 1.18
Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res (1988) 1.17
Molecular analysis of an EL4 cell line that expresses H-2Db but not H-2Kb or beta 2-microglobulin. Proc Natl Acad Sci U S A (1985) 1.11
The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA. Immunogenetics (1983) 1.07
Common antigenic structures of HL-A antigens. VI. Common antigenic determinants located on the 33,000 Dalton alloantigenic fragment portion of papain-solubilized HL-A molecules. Immunology (1975) 1.07
Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med (1989) 1.02
Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells. J Clin Invest (1989) 0.96
A mutational hot-spot within an intron of the mouse beta 2-microglobulin gene. EMBO J (1986) 0.95
Association of HL-A antigens and beta 2-microglobulin: concepts and questions. Transplant Rev (1974) 0.87
Production and properties of monoclonal antibodies to guinea pig Ia antigens. Methods Enzymol (1983) 0.87
Altered growth of a human neuroendocrine carcinoma line after transfection of a major histocompatibility complex class I gene. Proc Natl Acad Sci U S A (1989) 0.87
In vitro differentiation and antigenic changes in human melanoma cell lines. Cancer Immunol Immunother (1989) 0.84
High expression of the c-myc oncogene renders melanoma cells prone to lysis by natural killer cells. J Immunol (1989) 0.83
Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer (1989) 0.80
Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. J Immunol (1988) 0.77
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A (1992) 6.15
Genome sequence of the plant pathogen and biotechnology agent Agrobacterium tumefaciens C58. Science (2001) 5.16
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Photoinduced conversion of silver nanospheres to nanoprisms. Science (2001) 3.39
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Mitotic recombination in germ cells generated two major histocompatibility complex mutant genes shown to be identical by RNA sequence analysis: Kbm9 and Kbm6. Proc Natl Acad Sci U S A (1986) 3.15
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function. Science (1996) 2.83
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature (2001) 2.83
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol (1997) 2.60
HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med (1998) 2.50
HIV-1 subtype and second-receptor use. Nature (1996) 2.46
HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest (1999) 2.42
Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J Virol (1994) 2.36
Angiogenesis inhibited by drinking tea. Nature (1999) 2.31
Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet (1998) 2.31
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. J Immunol Methods (1976) 2.30
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Murine major histocompatibility complex class-I mutants: molecular analysis and structure-function implications. Annu Rev Immunol (1986) 2.29
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27
Gelatinase biosynthesis-activating pheromone: a peptide lactone that mediates a quorum sensing in Enterococcus faecalis. Mol Microbiol (2001) 2.22
Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A (2001) 2.11
Retroposon analysis of major cetacean lineages: the monophyly of toothed whales and the paraphyly of river dolphins. Proc Natl Acad Sci U S A (2001) 2.11
Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 2.06
Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q. Genomics (1999) 1.99
Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J Virol (1995) 1.98
Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4. AIDS Res Hum Retroviruses (1993) 1.94
Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med (1997) 1.83
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
A retrospective study of the application on double-balloon enteroscopy in 378 patients with suspected small-bowel diseases. Endoscopy (2007) 1.81
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Idiopathic CD4+ T-lymphocytopenia--immunodeficiency without evidence of HIV infection. N Engl J Med (1993) 1.77
Preponderance of slightly deleterious polymorphism in mitochondrial DNA: nonsynonymous/synonymous rate ratio is much higher within species than between species. Mol Biol Evol (1998) 1.76
Arsenic trioxide, a therapeutic agent for APL. Oncogene (2001) 1.72
The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. Oncogene (2001) 1.72
Nitric oxide is involved in phosphorus deficiency-induced cluster-root development and citrate exudation in white lupin. New Phytol (2010) 1.71
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol (1998) 1.69
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy. J Urol (1996) 1.69
Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today (1995) 1.69
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66
Linkage of a microsatellite marker to the canine copper toxicosis locus in Bedlington terriers. Am J Vet Res (1997) 1.65
IgG antibodies to HIV-1 in urine of HIV-1 seropositive individuals. Lancet (1988) 1.64
T1 alpha protein is developmentally regulated and expressed by alveolar type I cells, choroid plexus, and ciliary epithelia of adult rats. Am J Respir Cell Mol Biol (1996) 1.64
Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med (2001) 1.63
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med (1979) 1.63
Structural polymorphism of human DR antigens. Nature (1979) 1.63
Dopamine receptor subtypes colocalize in rat striatonigral neurons. Proc Natl Acad Sci U S A (1992) 1.62
A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem (2010) 1.59
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation (2001) 1.57
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A (2000) 1.57
Diabetes mellitus and the incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. Colorectal Dis (2012) 1.56
Genome-wide gene expression profiles of the developing mouse hippocampus. Proc Natl Acad Sci U S A (2001) 1.55
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Flexible use of high-density oligonucleotide arrays for single-nucleotide polymorphism discovery and validation. Genome Res (2001) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. Br J Cancer (2006) 1.53
The effect of peripherin/rds haploinsufficiency on rod and cone photoreceptors. J Neurosci (1997) 1.51
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Interaction between Kb and Q4 gene sequences generates the Kbm6 mutation. Mol Cell Biol (1986) 1.50
Cytokine regulation of IL-1 beta gene expression in the human polymorphonuclear leukocyte. J Immunol (1990) 1.49
Rodent polyphyly? Nature (1992) 1.49
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Computational method to reduce the search space for directed protein evolution. Proc Natl Acad Sci U S A (2001) 1.47
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens (2005) 1.45
Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii. Implications for the target of macrolide antibiotics. J Clin Invest (1995) 1.45
Development of the phytoplankton community in a pit-lake in relation to water quality changes. Water Res (2001) 1.44
Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol (1999) 1.43
Electronic properties of graphene encapsulated with different two-dimensional atomic crystals. Nano Lett (2014) 1.43
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
TAP off--tumors on. Immunol Today (1997) 1.43
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Mitotic recombination between homologous chromosomes generates H-2 somatic cell variants in vitro. Proc Natl Acad Sci U S A (1987) 1.40